論文・技術情報追加のお知らせ

1. Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data.

BCMA向けCAR-T療法の安全性シグナルを発見

対象DB：FAERS

2. Mining and analysis of adverse events profile of guanfacine using FDA adverse event reporting system (FAERS) database.

グアンファシンは新たな副作用シグナルを示す

対象DB：FAERS

3. Reproductive Toxicity Induced by Serotonin-Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database.

SNRIsは生殖毒性のリスクがあり、EDが頻発

対象DB：FAERS

4. A 13-years pharmacovigilance analysis of novel hormonal agents in prostate cancer using the FDA adverse event reporting system database.

新規ホルモン薬は血管・神経系に安全性シグナル

対象DB：FAERS

5. Vancomycin and linezolid: severe cutaneous adverse reactions to drugs.

バンコマイシンはSCARのリスクが高く、注意が必要

対象DB：FAERS

6. Post-licensure Safety Surveillance of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among US Adults in the Vaccine Adverse Event Reporting System (VAERS).

PCV20接種後のGBS報告増加、調査中

対象DB：FAERS,VAERS

7. A real-world disproportionality analysis of colchicine: data mining of the public version of FDA adverse event reporting system.

コルヒチンの有害事象と新たなシグナルの発見

対象DB：FAERS

8. Anticoagulant-associated calciphylaxis: analysis of USFDA Adverse Event Report System and clinical feature analysis of reported cases.

抗凝固薬によるカルシフィラキシスのリスクと管理

対象DB：FAERS

9. Interstitial lung disease with antibody-drug conjugates: a real-world pharmacovigilance study based on the FAERS database during the period 2014-2023.

抗体薬物複合体による間質性肺疾患のリスクと管理

対象DB：FAERS

10. Adverse reactions of immune checkpoint inhibitors combined with angiogenesis inhibitors: A pharmacovigilance analysis of drug-drug interactions.

免疫チェックポイント阻害剤と抗血管新生剤の相互作用リスク

対象DB：FAERS

11. Mogamulizumab-Associated Autoimmune Diseases: Insights From FAERS Database Analysis.

モガムリズマブ使用に関連する自己免疫疾患のリスク

対象DB：FAERS

12. The safety profile of usage of glucagon-like peptide-1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System.

妊婦へのGLP-1受容体作動薬使用の安全性分析

対象DB：FAERS

13. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for ramucirumab.

ラミシルマブの副作用に関するFAERS分析

対象DB：FAERS

14. The Association Between Dextromethorphan/Bupropion with Alcohol and Substance Misuse: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS) - CORRIGENDUM.

デキストロメトルファン/ブプロピオンと薬物乱用の関係

対象DB：FAERS

15. Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system.

プレカナチドの副作用シグナル、新たなリスクが確認

対象DB：FAERS

16. Post-marketing safety of panitumumab: a real-world pharmacovigilance study.

パニツムマブは新たな副作用シグナルを示す

対象DB：FAERS

17. Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database.

ロラゼパムは依存症や心臓障害のリスクあり

対象DB：FAERS

18. A comparative analysis of the safety profiles between inclisiran and other PCSK9 inhibitors from real-world evidence - what have we learned recently?

インクリシランは消化器や感染症に注意が必要

対象DB：FAERS

19. Mining and analysis of adverse event signals of trastuzumab deruxtecan via real-world data of FDA adverse event reporting system database from 2019 to 2023.

T-DXdは間質性肺疾患などの重篤な副作用を伴う

対象DB：FAERS

20. Real-World Safety Profile of Direct Oral Anticoagulants (DOACs): Disproportionality Analysis of Major Bleeding Events.

エドキサバンは他のDOACより出血リスクが高い

対象DB：FAERS

21. Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapy.

デュピルマブはCTCLの発症・進行と関連の可能性

対象DB：FAERS

22. Drug-induced megacolon in schizophrenia: a pharmacovigilance study of antipsychotic medications from the Japanese Adverse Drug Event database: a disproportionality analysis.

ゾテピン、スルピリド、クエチアピンが薬剤性巨大結腸症に関連

対象DB：JADER

23. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors on in-hospital mortality following pneumonia without heart failure: A retrospective cohort study of older adults with diabetes.

糖尿病患者の肺炎において、SGLT2iはDPP-4iと差なし

対象DB：DPC

24. Association between preoperative antifungal therapy and postoperative complications in patients with pulmonary aspergilloma: a national database study in Japan.

肺アスペルギルス症患者の術前抗真菌療法で合併症減少

対象DB：DPC

25. Comparison of open and laparoscopic appendectomy according to the trimester of pregnancy: A nationwide observational study.

妊娠中の虫垂炎手術では、腹腔鏡が後期に早産リスク増加

対象DB：DPC

26. Clinical Features and Prognosis of Malignant Cutaneous Adnexal Tumors: A Retrospective Study Using a Japanese Database.

日本での悪性皮膚付属器腫瘍は性別や年齢で予後が異なる

対象DB：DPC

27. Behcet's disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan.

日本でベーチェット病の治療にTNFα阻害薬使用増加

対象DB：JMDC

28. Hypnotics and Mortality in Idiopathic Pulmonary Fibrosis: Hospital and National Data-Based Analysis.

IPF患者で睡眠薬の継続使用は死亡リスク増加と関連

対象DB：NDB

29. Identifying Risk Factors of Major Adverse Cardiac Events in Patients With Ulcerative Colitis: A Retrospective Japanese Claims Data Analysis.

日本の潰瘍性大腸炎患者でMACEリスクは高齢や糖尿病が影響

対象DB：MDV

30. Contribution of infection to mortality in people with type 2 diabetes: a population-based cohort study using electronic records.

2型糖尿病患者は感染死リスクが高く過小評価されがち

対象DB：CPRD

31. Treatment patterns and burden of uncomplicated urinary tract infection in England.

非複雑性UTIは高コストで治療不適合も多い

対象DB：CPRD

32. Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum.

炎症性関節炎患者でガバペン使用は骨折リスク増加

対象DB：CPRD

33. Prevalence and patterns of testing for anaemia in primary care in England.

英国で貧血は高齢者や社会的弱者で多く、検査が不十分

対象DB：CPRD

34. Underlying disease risk among patients with fatigue: a population-based cohort study in primary care.

新規疲労患者は男性高齢者で癌リスクが高く、女性では低い

対象DB：CPRD